Overview

Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients

Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to evaluate the safety and tolerability of HM61713.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Hanmi Pharmaceutical Company Limited